Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Receivables - Other: 2020-2025

Historic Receivables - Other for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $1.8 million.

  • Caribou Biosciences' Receivables - Other rose 8.62% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 8.62%. This contributed to the annual value of $1.8 million for FY2024, which is 20.03% down from last year.
  • As of Q3 2025, Caribou Biosciences' Receivables - Other stood at $1.8 million, which was down 6.54% from $2.0 million recorded in Q2 2025.
  • Caribou Biosciences' Receivables - Other's 5-year high stood at $7.6 million during Q2 2021, with a 5-year trough of $1.5 million in Q2 2023.
  • Over the past 3 years, Caribou Biosciences' median Receivables - Other value was $1.8 million (recorded in 2025), while the average stood at $1.9 million.
  • As far as peak fluctuations go, Caribou Biosciences' Receivables - Other skyrocketed by 48.91% in 2021, and later tumbled by 59.94% in 2023.
  • Caribou Biosciences' Receivables - Other (Quarterly) stood at $5.5 million in 2021, then slumped by 59.02% to $2.2 million in 2022, then rose by 1.74% to $2.3 million in 2023, then fell by 20.03% to $1.8 million in 2024, then increased by 8.62% to $1.8 million in 2025.
  • Its Receivables - Other stands at $1.8 million for Q3 2025, versus $2.0 million for Q2 2025 and $1.8 million for Q1 2025.